AAPL343.20-0.26 (-0.08%) ▼|ABBV283.13-2.29 (-0.80%) ▼|ABT104.06-0.83 (-0.79%) ▼|ACN236.90+7.22 (+3.14%) ▲|ADBE247.09+1.89 (+0.77%) ▲|AMAT413.11+3.82 (+0.93%) ▲|AMD538.05+9.30 (+1.76%) ▲|AMGN424.94-7.55 (-1.75%) ▼|AMT183.05-2.22 (-1.20%) ▼|AMZN262.45+12.45 (+4.98%) ▲|AVGO334.59+5.84 (+1.78%) ▲|AXP316.37+2.78 (+0.88%) ▲|BA191.51+1.30 (+0.68%) ▲|BAC50.39-0.84 (-1.64%) ▼|BKNG162.60-0.85 (-0.52%) ▼|BLK1,124.83-9.56 (-0.84%) ▼|BMY58.84-0.91 (-1.52%) ▼|BNY142.41-0.89 (-0.62%) ▼|BRK-B532.47+0.45 (+0.08%) ▲|C121.72-2.54 (-2.04%) ▼|CAT725.77-4.99 (-0.68%) ▼|CL93.40-0.71 (-0.75%) ▼|CMCSA21.90+0.00 (+0.00%) ▲|COF199.86-1.88 (-0.93%) ▼|COP145.21-1.30 (-0.89%) ▼|COST995.53+6.42 (+0.65%) ▲|CRM242.46+1.76 (+0.73%) ▲|CSCO106.50-0.89 (-0.83%) ▼|CVS92.68+0.32 (+0.34%) ▲|CVX224.48-0.51 (-0.23%) ▼|DE627.30-14.56 (-2.27%) ▼|DHR224.39-4.65 (-2.03%) ▼|DIS109.58-1.01 (-0.91%) ▼|DUK119.26-2.21 (-1.82%) ▼|EMR160.52-0.95 (-0.59%) ▼|FDX293.81+0.26 (+0.09%) ▲|GD341.40-2.83 (-0.82%) ▼|GE311.34-2.49 (-0.79%) ▼|GEV908.35-12.85 (-1.39%) ▼|GILD153.07-3.12 (-2.00%) ▼|GM82.72-1.24 (-1.48%) ▼|GOOG340.16+3.25 (+0.96%) ▲|GOOGL344.18+3.59 (+1.05%) ▲|GS875.79-5.47 (-0.62%) ▼|HD309.99+0.36 (+0.12%) ▲|HON209.98-1.43 (-0.68%) ▼|IBM236.36+4.22 (+1.82%) ▲|INTC92.03+2.18 (+2.43%) ▲|INTU325.62+0.47 (+0.14%) ▲|ISRG433.18+6.48 (+1.52%) ▲|JNJ253.96-1.60 (-0.63%) ▼|JPM333.63-6.09 (-1.79%) ▼|KO93.44-0.47 (-0.50%) ▼|LIN503.44+5.01 (+1.01%) ▲|LLY1,240.40-16.63 (-1.32%) ▼|LMT548.45-3.64 (-0.66%) ▼|LOW195.90-1.48 (-0.75%) ▼|LRCX272.20+8.26 (+3.13%) ▲|MA616.27-1.15 (-0.19%) ▼|MCD242.63-0.34 (-0.14%) ▼|MDLZ63.34-0.57 (-0.89%) ▼|MDT92.74-2.01 (-2.12%) ▼|META705.44-3.89 (-0.55%) ▼|MMM162.10-2.65 (-1.61%) ▼|MO74.07-1.05 (-1.39%) ▼|MRK143.67-2.28 (-1.56%) ▼|MS178.49-2.08 (-1.15%) ▼|MSFT533.52+4.47 (+0.84%) ▲|MU904.90+26.06 (+2.97%) ▲|NEE78.18-1.62 (-2.03%) ▼|NFLX69.85-0.68 (-0.96%) ▼|NKE37.22+0.09 (+0.24%) ▲|NOW145.35+3.38 (+2.38%) ▲|NVDA217.09+2.96 (+1.38%) ▲|ORCL129.63+1.40 (+1.09%) ▲|PEP133.57+2.08 (+1.58%) ▲|PFE29.43-0.15 (-0.51%) ▼|PG157.71-1.64 (-1.03%) ▼|PLTR194.15+8.12 (+4.36%) ▲|PM200.98-4.22 (-2.06%) ▼|QCOM173.53+1.42 (+0.83%) ▲|RTX192.11-1.81 (-0.93%) ▼|SBUX97.87+0.35 (+0.36%) ▲|SCHW89.58-2.38 (-2.59%) ▼|SO89.27-1.91 (-2.09%) ▼|SPG202.49-2.95 (-1.44%) ▼|T23.20-0.24 (-1.02%) ▼|TMO679.28-10.72 (-1.55%) ▼|TMUS156.09-3.01 (-1.89%) ▼|TSLA368.06+13.34 (+3.76%) ▲|TXN276.15-0.33 (-0.12%) ▼|UBER69.96-0.39 (-0.55%) ▼|UNH406.88+5.45 (+1.36%) ▲|UNP287.01-2.03 (-0.70%) ▼|UPS97.46-0.02 (-0.02%) ▼|USB57.85-0.88 (-1.50%) ▼|V402.92+0.31 (+0.08%) ▲|VZ44.15-0.64 (-1.43%) ▼|WFC81.80-2.07 (-2.47%) ▼|WMT118.70-0.11 (-0.09%) ▼|XOM178.28-0.70 (-0.39%) ▼|AAPL343.20-0.26 (-0.08%) ▼|ABBV283.13-2.29 (-0.80%) ▼|ABT104.06-0.83 (-0.79%) ▼|ACN236.90+7.22 (+3.14%) ▲|ADBE247.09+1.89 (+0.77%) ▲|AMAT413.11+3.82 (+0.93%) ▲|AMD538.05+9.30 (+1.76%) ▲|AMGN424.94-7.55 (-1.75%) ▼|AMT183.05-2.22 (-1.20%) ▼|AMZN262.45+12.45 (+4.98%) ▲|AVGO334.59+5.84 (+1.78%) ▲|AXP316.37+2.78 (+0.88%) ▲|BA191.51+1.30 (+0.68%) ▲|BAC50.39-0.84 (-1.64%) ▼|BKNG162.60-0.85 (-0.52%) ▼|BLK1,124.83-9.56 (-0.84%) ▼|BMY58.84-0.91 (-1.52%) ▼|BNY142.41-0.89 (-0.62%) ▼|BRK-B532.47+0.45 (+0.08%) ▲|C121.72-2.54 (-2.04%) ▼|CAT725.77-4.99 (-0.68%) ▼|CL93.40-0.71 (-0.75%) ▼|CMCSA21.90+0.00 (+0.00%) ▲|COF199.86-1.88 (-0.93%) ▼|COP145.21-1.30 (-0.89%) ▼|COST995.53+6.42 (+0.65%) ▲|CRM242.46+1.76 (+0.73%) ▲|CSCO106.50-0.89 (-0.83%) ▼|CVS92.68+0.32 (+0.34%) ▲|CVX224.48-0.51 (-0.23%) ▼|DE627.30-14.56 (-2.27%) ▼|DHR224.39-4.65 (-2.03%) ▼|DIS109.58-1.01 (-0.91%) ▼|DUK119.26-2.21 (-1.82%) ▼|EMR160.52-0.95 (-0.59%) ▼|FDX293.81+0.26 (+0.09%) ▲|GD341.40-2.83 (-0.82%) ▼|GE311.34-2.49 (-0.79%) ▼|GEV908.35-12.85 (-1.39%) ▼|GILD153.07-3.12 (-2.00%) ▼|GM82.72-1.24 (-1.48%) ▼|GOOG340.16+3.25 (+0.96%) ▲|GOOGL344.18+3.59 (+1.05%) ▲|GS875.79-5.47 (-0.62%) ▼|HD309.99+0.36 (+0.12%) ▲|HON209.98-1.43 (-0.68%) ▼|IBM236.36+4.22 (+1.82%) ▲|INTC92.03+2.18 (+2.43%) ▲|INTU325.62+0.47 (+0.14%) ▲|ISRG433.18+6.48 (+1.52%) ▲|JNJ253.96-1.60 (-0.63%) ▼|JPM333.63-6.09 (-1.79%) ▼|KO93.44-0.47 (-0.50%) ▼|LIN503.44+5.01 (+1.01%) ▲|LLY1,240.40-16.63 (-1.32%) ▼|LMT548.45-3.64 (-0.66%) ▼|LOW195.90-1.48 (-0.75%) ▼|LRCX272.20+8.26 (+3.13%) ▲|MA616.27-1.15 (-0.19%) ▼|MCD242.63-0.34 (-0.14%) ▼|MDLZ63.34-0.57 (-0.89%) ▼|MDT92.74-2.01 (-2.12%) ▼|META705.44-3.89 (-0.55%) ▼|MMM162.10-2.65 (-1.61%) ▼|MO74.07-1.05 (-1.39%) ▼|MRK143.67-2.28 (-1.56%) ▼|MS178.49-2.08 (-1.15%) ▼|MSFT533.52+4.47 (+0.84%) ▲|MU904.90+26.06 (+2.97%) ▲|NEE78.18-1.62 (-2.03%) ▼|NFLX69.85-0.68 (-0.96%) ▼|NKE37.22+0.09 (+0.24%) ▲|NOW145.35+3.38 (+2.38%) ▲|NVDA217.09+2.96 (+1.38%) ▲|ORCL129.63+1.40 (+1.09%) ▲|PEP133.57+2.08 (+1.58%) ▲|PFE29.43-0.15 (-0.51%) ▼|PG157.71-1.64 (-1.03%) ▼|PLTR194.15+8.12 (+4.36%) ▲|PM200.98-4.22 (-2.06%) ▼|QCOM173.53+1.42 (+0.83%) ▲|RTX192.11-1.81 (-0.93%) ▼|SBUX97.87+0.35 (+0.36%) ▲|SCHW89.58-2.38 (-2.59%) ▼|SO89.27-1.91 (-2.09%) ▼|SPG202.49-2.95 (-1.44%) ▼|T23.20-0.24 (-1.02%) ▼|TMO679.28-10.72 (-1.55%) ▼|TMUS156.09-3.01 (-1.89%) ▼|TSLA368.06+13.34 (+3.76%) ▲|TXN276.15-0.33 (-0.12%) ▼|UBER69.96-0.39 (-0.55%) ▼|UNH406.88+5.45 (+1.36%) ▲|UNP287.01-2.03 (-0.70%) ▼|UPS97.46-0.02 (-0.02%) ▼|USB57.85-0.88 (-1.50%) ▼|V402.92+0.31 (+0.08%) ▲|VZ44.15-0.64 (-1.43%) ▼|WFC81.80-2.07 (-2.47%) ▼|WMT118.70-0.11 (-0.09%) ▼|XOM178.28-0.70 (-0.39%) ▼|
18 C
New York
Monday, October 19, 2026

Tag: gene therapy

newssourceFORcompanycontentinformation1releasesmarket

University of Bridgeport and Goodwin University Revolutionize Regenerative Medicine Training Program Forming Strategic Alliance with Globally Recognized TulsiHub Institute

BRIDGEPORT, CT, June 27, 2025 (GLOBE NEWSWIRE) -- The two leading academic institutions have joined forces with TulsiHub Institute, the premier provider of advanced CE certified regenerative medicine certification programs, to transform medical education standards across regenerative medicine and cellular therapy disciplines. This innovative alliance positions both universities as pioneers in cutting-edge healthcare training while establishing new industry standards for professional medical certifications and continuing medical education in the rapidly expanding regenerative healthcare sector.

Ophthalmology Drugs Market worth $26.28 billion by 2030 with 6.1% CAGR | MarketsandMarkets™

DELRAY BEACH, Fla., June 27, 2025 /PRNewswire/ -- The global Ophthalmology Drugs Market , valued at US$18.34 billion in 2024 stood at US$19.52 billion in 2025...

Ophthalmology Drugs Market worth $26.28 billion by 2030 with 6.1% CAGR | MarketsandMarkets™

DELRAY BEACH, Fla., June 27, 2025 /PRNewswire/ -- The global Ophthalmology Drugs Market , valued at US$18.34 billion in 2024 stood at US$19.52 billion in 2025...

EVA Pharma and BioPharma Town – Qiantang District, Hangzhou Sign a Strategic Cooperation Agreement

EVA Pharma Deepens Its Roots in China’s Thriving Biopharmaceutical Ecosystem with The Inauguration of Its Hangzhou Office 
EVA Pharma Deepens Its Roots in China’s Thriving Biopharmaceutical Ecosystem with The Inauguration of Its Hangzhou Office

Rocket Pharmaceuticals, Inc. (RCKT) Faces Securities Class Action Amid Protocol Change and FDA’s Clinical Hold on Gene Therapy Trial – Hagens Berman

SAN FRANCISCO, June 25, 2025 (GLOBE NEWSWIRE) -- A securities class action lawsuit styled Ho v. Rocket Pharmaceuticals, Inc., et al., No. 3:25-cv-10049 (D. N.J.) has been filed and seeks to represent investors who purchased or otherwise acquired Rocket Pharmaceuticals securities between February 27, 2025 and May 26, 2025.

Liver Disease Treatments: Global Market Forecast and Emerging Trends Through 2030

"Rising liver disease cases and biotech innovations are fueling demand for advanced therapies, with personalized medicine and fibrosis-targeting treatments shaping the global market landscape." BOSTON,...

Liver Disease Treatments: Global Market Forecast and Emerging Trends Through 2030

"Rising liver disease cases and biotech innovations are fueling demand for advanced therapies, with personalized medicine and fibrosis-targeting treatments shaping the global market landscape." BOSTON,...

Genprex Collaborators Present Positive Preclinical Research on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions

Latest Research Demonstrates Promising Improved Glucose Homeostasis by Reprogramming Alpha Cells AUSTIN, Texas, June 24, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a...

Ascidian Therapeutics Appoints Dr. Murray A. Abramson as Chief Development Officer and Establishes Ophthalmology Clinical Advisory Board to Advance ACDN-01 for Treatment of Stargardt...

BOSTON, June 24, 2025 /PRNewswire/ -- Ascidian Therapeutics, a biotechnology company seeking to treat human diseases by rewriting RNA, today announced the appointment of Murray...

Bio-Techne and USP Announce Collaboration to Accelerate Monoclonal Antibody and Gene Therapy Product Development

MINNEAPOLIS, June 24, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced a distribution agreement with the U.S. Pharmacopeia (USP) that enables the Company...

Rocket Pharmaceuticals, Inc. (RCKT) Faces Securities Class Action Amid Protocol Change and FDA’s Clinical Hold on Gene Therapy Trial – Hagens Berman

SAN FRANCISCO, June 23, 2025 (GLOBE NEWSWIRE) -- A securities class action lawsuit styled Ho v. Rocket Pharmaceuticals, Inc., et al., No. 3:25-cv-10049 (D. N.J.) has been filed and seeks to represent investors who purchased or otherwise acquired Rocket Pharmaceuticals securities between February 27, 2025 and May 26, 2025.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rocket Pharmaceuticals, Inc. – RCKT

NEW YORK, June 22, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Rocket Pharmaceuticals, Inc. ("Rocket" or the "Company")...

Saudi Arabia Concludes Landmark BIO 2025 Debut as Kingdom Opens Doors to Global Biotech Collaboration

From genomics to regulatory innovation, the Kingdom’s presence in Boston establishes it as a major partner in global health science 
From genomics to regulatory innovation, the Kingdom’s presence in Boston establishes it as a major partner in global health science

2024 Cell and Gene Therapy Market Set for Breakthrough Growth, Says BCC Research

"Comprehensive Review Highlights Market Growth, Innovation, and Investment Trends Driving the Future of Cell and Gene Therapy Tools, Biomanufacturing, and Gene Synthesis" BOSTON, June 20, 2025...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsGene therapy

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers